Scinai Immunotherapeutics Ltd - ADR SCNI

NAS: SCNI | ISIN: US09073Q2049   11/07/2025
2,315 USD (+0,65%)
(+0,65%)   11/07/2025

7 mei 2025 · Scinai Announces Annual Financial Results for 2024 · Persbericht

1 mei 2025 · Scinai Immunotherapeutics and Pincell to Host Webinar on a Blockbuster Drug Candidate for Devastating Rare Skin Diseases · Persbericht

27 maart 2025 · Scinai signs an option agreement to acquire rare disease company Pincell and its novel antibody for treating Severe Dermatological Conditions · Persbericht

17 maart 2025 · Scinai to Connect with Investors, Showcase its Innovative I&I pipeline and its Boutique cGMP Biologics CDMO during BIO-Europe Spring 2025 · Persbericht

5 maart 2025 · Scinai Immunotherapeutics Announces $10 Million Standby Equity Purchase Agreement · Persbericht

29 augustus 2024 · Scinai Regains Full Compliance with Nasdaq Listing Requirements · Persbericht

21 augustus 2024 · Scinai Announces Closing of Loan Restructuring Agreement with European Investment Bank Converting Approximately $29 million of Debt to Preferred Equity and Leaving Debt Balance of $273,000 · Persbericht

20 augustus 2024 · Scinai Announces Entering into $2 Million Private Equity Commitment Agreement with its largest Existing Shareholder · Persbericht

15 augustus 2024 · Scinai Publishes Q2 2024 Financial Results and Provides Business Update; Restructures $29 Million Bank Loan to Equity; On Track to Regain Nasdaq Compliance by August 23 · Persbericht

13 augustus 2024 · Scinai Announces Signing of Loan Restructuring Agreement with European Investment Bank; Converting Approximately $29 million of Debt to Preferred Equity Convertible into 19.5% Common Equity · Persbericht

23 juli 2024 · Scinai Immunotherapeutics Announces Positive Regulatory Feedback from the PEI on the path for Phase 1/2a in Plaque Psoriasis with its anti-IL-17 nanoAb · Persbericht

15 juli 2024 · Scinai Immunotherapeutics Announces promising results in an in-vivo proof-of-concept psoriatic human skin model · Persbericht

8 juli 2024 · Scinai Immunotherapeutics Announces Receipt of an Updated Letter of Intent from the European Investment Bank Providing Specific Terms for Conversion of its Loan to Equity · Persbericht

3 juli 2024 · Scinai Immunotherapeutics Granted Extension by Nasdaq Hearing Panel to Regain Compliance with Continued Listing Requirements · Persbericht

2 juli 2024 · Scinai Publishes Q1 2024 Financial Results and Provides Business Update · Persbericht

13 juni 2024 · Scinai Immunotherapeutics Announces Receipt of a Letter of Intent from the European Investment Bank Providing Specific Terms for Conversion of its Loan to Equity. · Persbericht

7 juni 2024 · Scinai Immunotherapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement; Continues to Work with the European Investment Bank to Convert Loan to Equity to Regain Compliance with Nasdaq Minimum Shareholders' Equity Requirement · Persbericht

24 mei 2024 · Scinai Immunotherapeutics Announces Receipt of a Nasdaq Staff Determination Letter Regarding Shareholders' Equity listing requirements and Hearing to Present a Plan for Regaining Compliance · Persbericht

15 mei 2024 · Scinai Publishes FY 2023 Financial Statements, Files Annual Report on Form 20-F and Provides Business Update · Persbericht

6 mei 2024 · Scinai Immunotherapeutics Announces Receipt of Nasdaq Delisting Notification and Appeal · Persbericht

Mijn selecties